Old Web
English
Sign In
Acemap
>
authorDetail
>
Ivette Revollo
Ivette Revollo
Boehringer Ingelheim
Medicine
Linagliptin
QT interval
Placebo
Pharmacology
3
Papers
27
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
FC 049A RANDOMISED DOSE RANGING, PLACEBO-CONTROLLED, PHASE II STUDY ASSESSING THE EFFICACY AND SAFETY OF BI 655064, AN ANTAGONISTIC ANTI-CD40 ANTIBODY, IN PATIENTS WITH LUPUS NEPHRITIS
2021
Nephrology Dialysis Transplantation
David Jayne
Richard Furie
Juanita Romero-Diaz
Hirofumi Amano
Kajohnsak Noppakun
Harold Michael Gomez
Rhona Recto
Valerie Belsack
Nora M. Fagan
Steven J. Padula
Ivette Revollo
Jing Wu
Sudha Visvanathan
Jürgen Steffgen
Show All
Source
Cite
Save
Citations (0)
The DPP-4 inhibitor linagliptin does not prolong the QT interval at therapeutic and supratherapeutic doses.
2011
British Journal of Clinical Pharmacology
Arne Ring
A. Port
E. Ulrike Graefe‐Mody
Ivette Revollo
Mario Iovino
Klaus Dugi
Show All
Source
Cite
Save
Citations (27)
Linagliptin, a potent and selective DPP-4 inhibitor, does not prolong the QT interval when given in therapeutic and 20-fold supratherapeutic doses
2010
Arne Ring
Ulrike Graefe-Mody
A. Port
Ivette Revollo
Beate Walter
Hans-Juergen Woerle
Mario Iovino
Klaus Dugi
Show All
Source
Cite
Save
Citations (0)
1